BeOne Medicines (BEIGF) Non-Current Debt (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Non-Current Debt data on file, last reported at $962.5 million in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $962.5 million, up 500.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $962.5 million (up 500.98% YoY), and the FY2025 annual result was $961.9 million, up 477.78% from the prior year.
• Non-Current Debt was little changed at $962.5 million in Q1 2026 per BEIGF's latest filing, from $961.9 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $962.5 million in Q1 2026 and troughed at $146.1 million in Q2 2025.
• A 5-year average of $318.8 million and a median of $201.6 million in 2022 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt decreased 21.15% in 2025, then soared 500.98% in 2026.
• A 5-year view of Non-Current Debt shows it stood at $209.1 million in 2022, then decreased by 5.51% to $197.6 million in 2023, then retreated by 15.75% to $166.5 million in 2024, then surged by 477.78% to $961.9 million in 2025, then gained by 0.06% to $962.5 million in 2026.
• Business Quant data shows BEIGF's Non-Current Debt at $962.5 million in Q1 2026, $961.9 million in Q4 2025, and $832.8 million in Q3 2025.